Revisiting cardiovascular risk reduction in type 2 diabetes and dyslipidemia

Statin therapy has been a mainstay of cardiovascular disease (CVD) risk reduction for the past 20 years in type 2 diabetes management. Its application has been largely due to well-designed, randomized-control studies consistently showing 25–35% CVD risk reduction. However, the remaining 65–75% reduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Phillip, Bleich, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434405/
https://www.ncbi.nlm.nih.gov/pubmed/36060284
http://dx.doi.org/10.1016/j.ijcrp.2022.200141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434405/
https://www.ncbi.nlm.nih.gov/pubmed/36060284
http://dx.doi.org/10.1016/j.ijcrp.2022.200141

Ejemplares similares